跳至主要内容
临床试验/NCT00376038
NCT00376038已完成1 期

A Randomized Open-label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects With Type 2 Diabetes Mellitus.

GlaxoSmithKline2 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2006年8月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
13
试验地点
2
主要终点
Blood concentrations of metformin when given with GSK189075 in T2DM subjects over 3-day course Lab tests, changes in blood pressure and heart rate and heart activity on EKG machine

研究概览

简要总结

GSK189075 is intended for use as a single treatment or in combination with other treatments for tye 2 diabetes mellitus (T2DM). Metformin is widely used in Europe and the USA for the treatment of T2DM. This study will evaluate the effect of GSK189075 on metformin levels in the blood in T2DM subjects. The rationale is to look for any safety problems that may result when the 2 drugs are given together.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Have Type 2 diabetes mellitus.
  • Have a Body Mass Index within range 22 to 35kg/m2 inclusive.
  • Females who meet above criteria must be physiologically incapable of becoming pregnant (i.e., surgically sterilized, or post-menopausal per protocol definition).

排除标准

  • Are currently taking insulin therapy.
  • Have any disease (such as heart, liver, blood, nervous system, or kidney disease, or cancer).
  • Have a history of stomach, liver, kidney, or other disease that with interfere with taking the study drug.
  • Are currently using diuretics, oral or injectable corticosteroids (inhaled & intranasal corticosteroids are permitted), or other medications that would cause you to deplete your fluid balance in your body; currently taking stable regimens for heart conditions; currently using prescription or non-prescription drugs within 7 days of starting the study that may interfere with the study drug.
  • Would donate more than 450 ML of blood over a 2 month period.
  • Physician does not think it is a good idea for you to participate in the trial. - Had a urinary tract infection or bladder infection in the last month. - Are currently drinking more than 2 beers, 1 glass of wine, or 1 glass of spirits daily.
  • Have a positive urine drug screen test.
  • Plan to change your smoking habits during the course of the trial.
  • Have Hepatitis C, Hepatitis B, or HIV. - Have a lab or EKG abnormality. - High or low blood pressure.
  • Have used of any investigational drug or device during the study or within 30 days prior to 1st dosing of study medication.
  • Are a male subject unwilling to abstain or use protection during intercourse.

结局指标

主要结局

Blood concentrations of metformin when given with GSK189075 in T2DM subjects over 3-day course Lab tests, changes in blood pressure and heart rate and heart activity on EKG machine

次要结局

  • Blood levels of drugs at Day 3 Evaluation of efficacy and safety markers on Days 1, 2, and 3.

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验